Back to top

crispr: Archive

Zacks Equity Research

Vertex (VRTX), CRISPR Get Positive CHMP Opinion for Gene-Therapy

Vertex (VRTX) and CRISPR get a positive CHMP opinion, recommending the conditional approval of Casgevy for the treatment of SCD and TDT.

VRTXPositive Net Change BLUENegative Net Change EDITNegative Net Change CRSPNegative Net Change

Zacks Equity Research

Editas (EDIT) Licenses Cas9 Tool to Vertex, Stock Up 6%

Editas (EDIT) stock rises 6% on a non-exclusive agreement with Vertex Pharmaceuticals to license its Cas9 gene-editing technology for the development of the latter's gene therapy drug, Casgevy.

VRTXPositive Net Change BLUENegative Net Change EDITNegative Net Change CRSPNegative Net Change